SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective for SMARCA4-deficient lung cancer and malignant rhabdoid tumor-like tumors. Here, we describe a patient with SMARCA4-DTC who experienced a marked response to the administration of pembrolizumab. A 70-yearold female was referred to our department for treatment of SMARCA4-DTC. Positron emission tomography-computed tomography had revealed a left mediastinal tumor, peritoneal dissemination and multiple cutaneous metastases at diagnosis. Immunohistochemical analyses revealed 60% of tumor cells expressed programmed cell death ligand 1 (PD-L1). The patient was given pembrolizumab as first-line treatment. Pembrolizumab suppressed tumor growth dramatically, with only one dose leading to a partial response. Our case suggests the immunohistochemical analysis of PD-L1 expression be undertaken for patients with SMARCA4-DTS and that pembrolizumab treatment may be a promising strategy for PD-L1-positive SMARCA4-DTS.
Introduction
SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) has been established as a novel category of malignancy, distinct from lung cancer but related to a SMARCB1inactivated malignant rhabdoid tumor (MRT) and SMARCA4-mutated small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT). 1-3 SMARCA4-DTS is characterized by lethal and aggressive thoracic tumors induced by the loss of SMARCA4, also termed Brahma-related gene 1 (BRG1), which is a member of the polybromo-and BRG1-associated factor (PBAF) form of switch-sucrose nonfermentable chromatin remodeling complexes. 4 The prognosis for SMARCA4-DTS cases is poor, with median overall survival around six months because treatment strategies for this disease have not been established. 1, 5 Accumulating evidence has revealed that the clinical benefit of antiprogrammed cell death 1 receptor (PD-1) blockade was associated with the loss of function of PBAF complexes in a subset of malignancies. 6, 7 Most recently, it has been reported that anti-PD-1 blockade was effective for patients with SMARCA4-deficient tumors. 8, 9 However, the mechanisms of antitumor activities that induced anti-PD-1 blockade have not been fully elucidated. In fact, two cases with SMARCA4-DTS successfully treated by anti-PD-1 blockade did not express programmed cell death ligand 1 (PD-L1) in their tumors.
In this report, we describe a rapid and major response to pembrolizumab in a case of SAMRCA4-DTS that overexpressed PD-L1.
Case report
A 69-year-old female presented to a previous hospital with an initial diagnosis of malignant lymphoma by means of biopsy from a right breast tumor. However, clinical signs and pathological findings did not support the diagnosis of malignant lymphoma. Therefore, a second biopsy of another cutaneous tumor in the lower anterior abdomen was carried out. Finally, the patient was diagnosed with SMARCA4-DTS and referred to our department.
The patient's main complaints were a palpable multiple cutaneous mass, lower abdominal pain and bloody sputum. A positron emission tomography (PET)-computed tomography (CT) scan revealed a left mediastinal tumor, peritoneal and retroperitoneal dissemination and multiple cutaneous metastases (Fig 1a,b) . Histologically, the tumor consisted of a sheet-like proliferation of polyhedral tumor cells with an eosinophilic cytoplasm, and enlarged round nuclei with vesicular nuclear chromatin and conspicuous nucleoli (Fig 2a) . The resected tumor showed massive foci of necrosis. Small-sized lymphocytes were intermingled with tumor cells (Fig 2a) . On immunohistochemistry, the tumor cells were positive for SMARCA2 (INI1; Fig 2b) and negative for SMARCA4 (BRG1; Fig 2c) . The tumor cells also showed high PD-L1 expression (>60%; Fig 2d) . The expression of DNA mismatch repair proteins, such as MLH1, MSH2, MSH6, and PMS2, was retained. Background lymphocytes included both CD4-positive (Fig 2e) and CD8-positive T-lymphocytes (Fig 2f) . Microsatellite instability status was stable tested by PCR (Falco Biosystems, Kyoto, Japan). We treated the patient with pembrolizumab as a first-line treatment because of high PD-L1 expression in tumor cells. After one pembrolizumab infusion, the patient's abdominal pain and bloody sputum were resolved, suggesting a possible clinical benefit. Strikingly, a CT scan demonstrated a partial response (PR; Fig 1c) . A CT scan after eight cycles of pembrolizumab demonstrated a sustained durable PR response with no adverse events (Fig 1d) . Written informed consent was obtained from the patient for the publication of all clinical data and images.
Discussion
We describe the successful treatment of a patient with PD-L1 overexpressing SARCA4-DTS by pembrolizumab. Of note, two previous reports showed that anti-PD-1 blockade was effective for patients with SMARCA4-deficient tumors that, in contrast to our present case, did not express PD-L1. 8, 9 This is the first case to show overexpressed PD-L1 in tumors in a patient with SMARCA4-DTS. The majority of cases with SCCOHT, which is similar to SMARCA4-DTS, exhibited PD-L1 expression and massive T-cell infiltration around tumors that suggested SCCOHT to be an immunogenic tumor. 3 In fact, four cases of SCCOHT achieved major responses to anti-PD-1 blockade. According to the immune phenotypes of SCCOHT, it may be that SMARCA4 defects induce PD-L1 expression in tumors. However, patients with SMARCA4-DTS did not express PD-L1 and show infiltration of T-cells in tumors, unlike in SCCOHT and our case. 1, 8 The relationship between SMARCA4 deficiencies and immunogenicity needs to be examined further.
The mechanisms that determine sensitivity to anti-PD-1 blockade remain to be fully elucidated. Growing evidence suggests such mechanisms include the high expression of PD-L1, DNA mismatch-repair deficiency, a high tumor mutational burden, an interferon (IFN)-γ signature and the presence of CD8+ T cells. [10] [11] [12] [13] [14] In our case, plausible mechanisms for the dramatic response to pembrolizumab may include PD-L1 overexpressed in tumors and the dysfunction of PBAF associated with the loss of SMACA4. The loss of PBAF function may induce the upregulation of IFN-γ-responsive genes and secretion of T cell chemoattractants to recruit effector T cells to tumors. 6 Therefore, dysfunction of such chromatin remodeling complexes can lead to the increased efficacy of an anti-PD-1 blockade against malignant tumors.
Our case suggests that anti-PD-1 blockade may be effective for PD-L1 expressing SMARCA4-DTC. We should therefore determine the expression of PD-L1 in SMARCA4-DTC to consider all treatment options. 
